Common Contracts
1 similar Translation contracts
Chugai to In-license Hedgehog Pathway Inhibitor “RG3616”Translation • February 19th, 2010
February 19, 2010 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] has entered into a license agreement with F. Hoffmann-La Roche, Ltd [Head Office: Basel, Switzerland / CEO: Severin Schwan (hereafter, “Roche”)] for the hedgehog pathway inhibitor “RG3616,” which is currently in clinical development outside of Japan for advanced basal cell carcinoma, metastatic colorectal cancer and advanced ovarian cancer by Roche and Genentech Inc. [California,
